• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FDA Panel Votes to Expand Use of Pneumococcal Vaccine to Adults

Article

An FDA advisory committee has voted 14-1 in favor of expanding the indication for the pneumococcal 13-valent conjugate vaccine (Prevnar 13) to include use in adults 50 and older.

Currently the vaccine is approved only for use in children.

The FDA's Vaccines and Related Biologics Advisory Committee voted for accelerated approval, reserved for biologics or drugs that are intended to treat serious or life-threatening illnesses and that provide a meaningful benefit over existing treatments.

Read the full story at: http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755

Source: MedPage Today

Related Videos
Dr Susan Vadaparampil
Luke Messac at ISC 2026
2 experts are featured in this series.
Ava Liberman at ISC 2026
Alison Holman at ISC 2026
Dr Ameet Patel
Linda Stein Gold, MD
Eric Levin, Scripta
Dr. Emily Fisher at ISC 2026
© 2026 MJH Life Sciences
AJMC®
All rights reserved.